Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG CLASS:

KRAS inhibitor

DRUG CLASS:

KRAS inhibitor

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Related drugs:

‹

anti-KRAS G12D mTCR PBL (0)

anti-KRAS oligonucleotide therapeutic (0)

library TCR-T-cell therapy (0)

mDC3/8-KRAS vaccine (0)

mutant-specific KRAS inhibitor (0)

p53/KRAS/EGFR targeted NK cell therapy (0)

JNJ-74699157 (0)

KRAS G12D targeted T-cell therapy (0)

KRAS peptide vaccine (0)

KRAS4B inhibitor (0)

Kras inhibitor (0)

MSC-derived Exosomes with KrasG12D siRNA (0)

Mutant KRAS inhibitor (0)

SQZ-AAC-KRAS (0)

SQZ-APC-KRAS (0)

anti-KRAS G12D mTCR PBL (0)

anti-KRAS oligonucleotide therapeutic (0)

library TCR-T-cell therapy (0)

mDC3/8-KRAS vaccine (0)

mutant-specific KRAS inhibitor (0)

p53/KRAS/EGFR targeted NK cell therapy (0)

›

KRAS mutation	Lung Adenocarcinoma	KRAS mutation	Lung Adenocarcinoma	KRAS inhibitor Resistant: C3 – Early Trials KRAS inhibitor Resistant : C3	KRAS inhibitor Resistant: C3 – Early Trials KRAS inhibitor Resistant : C3
KRAS G12C + ATM wild-type	Non Small Cell Lung Cancer	KRAS G12C + ATM wild-type	Non Small Cell Lung Cancer	KRAS inhibitor Resistant: C3 – Early Trials KRAS inhibitor Resistant : C3	KRAS inhibitor Resistant: C3 – Early Trials KRAS inhibitor Resistant : C3
KRAS G12C + SMARCA4 wild-type	Non Small Cell Lung Cancer	KRAS G12C + SMARCA4 wild-type	Non Small Cell Lung Cancer	KRAS inhibitor Sensitive: C3 – Early Trials KRAS inhibitor Sensitive : C3	KRAS inhibitor Sensitive: C3 – Early Trials KRAS inhibitor Sensitive : C3
KRAS mutation	Multiple Myeloma	KRAS mutation	Multiple Myeloma	AZD4785 Sensitive: D – Preclinical AZD4785 Sensitive : D	AZD4785 Sensitive: D – Preclinical AZD4785 Sensitive : D
KRAS G12C + KRAS G12V	Non Small Cell Lung Cancer	KRAS G12C + KRAS G12V	Non Small Cell Lung Cancer	AZ’8037 Resistant: D – Preclinical AZ’8037 Resistant : D	AZ’8037 Resistant: D – Preclinical AZ’8037 Resistant : D
KRAS G12C	Solid Tumor	KRAS G12C	Solid Tumor	TEB-17231 Sensitive: D – Preclinical TEB-17231 Sensitive : D	TEB-17231 Sensitive: D – Preclinical TEB-17231 Sensitive : D